Jennifer M Connelly, MD | Medical College of Wisconsin

Jennifer M. Connelly, MD

Associate Professor

Request an Appointment

Location

Cancer Center - Froedtert Hospital
8800 West Doyne Ave.
Milwaukee, WI 53226

Specialties

Neurology
Neuro-Oncology

Cancer Center - Froedtert Menomonee Falls Hospital

(262) 257-5100

Cancer Center - Froedtert Hospital

(414) 805-0505

My focus on every patient is not only on managing treatment of the tumor and prolonging life but also in maintaining quality of life with the tools we have available.

Overview

Diseases and Conditions

Brain Tumors
Metastases to the Nervous System
Neurofibromatosis (NF)
Neurologic Complications of Cancer and Cancer Therapies
Neurologic Paraneoplastic Syndromes
Neuromuscular Disease
Spine and Spinal Cord Tumors
Neurocutaneous Syndromes
Brain Metastasis

Treatments and Services

Virtual Visit

Patients Ages Seen

Adult
Senior

Languages

English

Hospital Affiliations

Froedtert Hospital – Milwaukee
Froedtert Menomonee Falls Hospital – Menomonee Falls

Board Certifications

Internal Medicine
Neurology
Neuro-Oncology

Clinic Locations

Cancer Center - Froedtert Hospital

8800 West Doyne Ave.
Milwaukee, WI 53226
(866) 680-0505
Get Directions

Cancer Center - Froedtert Menomonee Falls Hospital

W180 N8085 Town Hall Road
Menomonee Falls, WI 53051
(262) 251-1000
Get Directions

Biography

Dr. Jennifer Connelly’s expertise includes the diagnosis and treatment of a wide array of brain and spine tumors. More specifically, she is focused on tumors that begin or have spread (metastasized) to the brain or spine. In addition, her clinical interests include evaluating and treating neurologic complications of cancer and cancer therapies (including paraneoplastic syndromes seizures, and neuropathies). Her research interests include molecular pathology as well as development of advanced MRI imaging techniques for diagnosing and treating brain and spinal cord tumors. Her holistic patient-centered care focuses on improving quality of life outcomes for brain and spine tumor patients. A native of the Milwaukee area, Dr. Connelly has received all of her training at the Medical College of Wisconsin. Dr. Connelly is board certified in Internal Medicine, Neurology and Neuro-Oncology.

Education and Training

Doctor of Medicine - Medical College of Wisconsin - Milwaukee, WI (2003)
Fellowship in Neuro-Oncology - Medical College of Wisconsin Affiliated Hospitals - Milwaukee, WI (2008-2009)
Residency in Internal Medicine and Neurology - Medical College of Wisconsin Affiliated Hospitals - Milwaukee, WI (2003-2008)

NRG/RTOG 1122: A phase 2, double-blinded, placebo-controlled study of bevacizumab with and without trebananib in patients with recurrent glioblastoma or gliosarcoma.

(Lee EQ, Zhang P, Wen PY, Gerstner ER, Reardon DA, Aldape KD, deGroot JF, Pan E, Raizer JJ, Kim LJ, Chmura SJ, Robins HI, Connelly JM, Battiste JD, Villano JL, Wagle N, Merrell RT, Wendland MM, Mehta MP.) Cancer. 2020 Jun 15;126(12):2821-2828 PMID: 32154928 PMCID: PMC7245544 SCOPUS ID: 2-s2.0-85081276146 03/11/2020
Longitudinal molecular trajectories of diffuse glioma in adults.

(Barthel FP, Johnson KC, Varn FS, Moskalik AD, Tanner G, Kocakavuk E, Anderson KJ, Abiola O, Aldape K, Alfaro KD, Alpar D, Amin SB, Ashley DM, Bandopadhayay P, Barnholtz-Sloan JS, Beroukhim R, Bock C, Brastianos PK, Brat DJ, Brodbelt AR, Bruns AF, Bulsara KR, Chakrabarty A, Chakravarti A, Chuang JH, Claus EB, Cochran EJ, Connelly J, Costello JF, Finocchiaro G, Fletcher MN, French PJ, Gan HK, Gilbert MR, Gould PV, Grimmer MR, Iavarone A, Ismail A, Jenkinson MD, Khasraw M, Kim H, Kouwenhoven MCM, LaViolette PS, Li M, Lichter P, Ligon KL, Lowman AK, Malta TM, Mazor T, McDonald KL, Molinaro AM, Nam DH, Nayyar N, Ng HK, Ngan CY, Niclou SP, Niers JM, Noushmehr H, Noorbakhsh J, Ormond DR, Park CK, Poisson LM, Rabadan R, Radlwimmer B, Rao G, Reifenberger G, Sa JK, Schuster M, Shaw BL, Short SC, Smitt PAS, Sloan AE, Smits M, Suzuki H, Tabatabai G, Van Meir EG, Watts C, Weller M, Wesseling P, Westerman BA, Widhalm G, Woehrer A, Yung WKA, Zadeh G, Huse JT, De Groot JF, Stead LF, Verhaak RGW, GLASS Consortium.) Nature. 2019 12;576(7785):112-120 PMID: 31748746 PMCID: PMC6897368 SCOPUS ID: 2-s2.0-85075234677 11/22/2019
High-dose intravenous methotrexate in the management of breast cancer with leptomeningeal disease: Case series and review of the literature.

(Kapke JT, Schneidewend RJ, Jawa ZA, Huang CC, Connelly JM, Chitambar CR.) Hematol Oncol Stem Cell Ther. 2019 Dec;12(4):189-193 PMID: 31629723 SCOPUS ID: 2-s2.0-85075443191 10/21/2019
Moving Toward a Consensus DSC-MRI Protocol: Validation of a Low-Flip Angle Single-Dose Option as a Reference Standard for Brain Tumors.

(Schmainda KM, Prah MA, Hu LS, Quarles CC, Semmineh N, Rand SD, Connelly JM, Anderies B, Zhou Y, Liu Y, Logan B, Stokes A, Baird G, Boxerman JL.) AJNR Am J Neuroradiol. 2019 04;40(4):626-633 PMID: 30923088 PMCID: PMC6461489 SCOPUS ID: 2-s2.0-85064588009 03/30/2019
Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.

(Prah MA, Al-Gizawiy MM, Mueller WM, Cochran EJ, Hoffmann RG, Connelly JM, Schmainda KM.) J Neurooncol. 2018 Jan;136(1):13-21 PMID: 28900832 PMCID: PMC5756123 SCOPUS ID: 2-s2.0-85029185195 09/14/2017
Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency.

(Doan NB, Alhajala H, Al-Gizawiy MM, Mueller WM, Rand SD, Connelly JM, Cochran EJ, Chitambar CR, Clark P, Kuo J, Schmainda KM, Mirza SP.) Oncotarget. 2017 Dec 22;8(68):112662-112674 PMID: 29348854 PMCID: PMC5762539 01/20/2018
Acid ceramidase confers radioresistance to glioblastoma cells.

(Doan NB, Nguyen HS, Al-Gizawiy MM, Mueller WM, Sabbadini RA, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP.) Oncol Rep. 2017 Oct;38(4):1932-1940 PMID: 28765947 PMCID: PMC5652937 SCOPUS ID: 2-s2.0-85029804998 08/03/2017
Acid ceramidase is a novel drug target for pediatric brain tumors.

(Doan NB, Nguyen HS, Montoure A, Al-Gizawiy MM, Mueller WM, Kurpad S, Rand SD, Connelly JM, Chitambar CR, Schmainda KM, Mirza SP.) Oncotarget. 2017 Apr 11;8(15):24753-24761 PMID: 28445970 PMCID: PMC5421885 SCOPUS ID: 2-s2.0-85017541087 04/28/2017
A state-of-the-art review and guidelines for tumor treating fields treatment planning and patient follow-up in glioblastoma.

(Trusheim J, Dunbar E, Battiste J, Iwamoto F, Mohile N, Damek D, Bota DA, Connelly J.) CNS Oncol. 2017 01;6(1):29-43 PMID: 27628854 PMCID: PMC6027938 SCOPUS ID: 2-s2.0-85050579311 09/16/2016
Progressing Bevacizumab-Induced Diffusion Restriction Is Associated with Coagulative Necrosis Surrounded by Viable Tumor and Decreased Overall Survival in Patients with Recurrent Glioblastoma.

(Nguyen HS, Milbach N, Hurrell SL, Cochran E, Connelly J, Bovi JA, Schultz CJ, Mueller WM, Rand SD, Schmainda KM, LaViolette PS.) AJNR Am J Neuroradiol. 2016 Dec;37(12):2201-2208 PMID: 27492073 PMCID: PMC5161572 SCOPUS ID: 2-s2.0-85006469905 08/06/2016
Planning TTFields treatment using the NovoTAL system-clinical case series beyond the use of MRI contrast enhancement.

(Connelly J, Hormigo A, Mohilie N, Hu J, Chaudhry A, Blondin N.) BMC Cancer. 2016 11 04;16(1):842 PMID: 27809808 PMCID: PMC5096303 SCOPUS ID: 2-s2.0-84994355377 11/05/2016
Location of brain tumor intersecting white matter tracts predicts patient prognosis.

(Mickevicius NJ, Carle AB, Bluemel T, Santarriaga S, Schloemer F, Shumate D, Connelly J, Schmainda KM, LaViolette PS.) J Neurooncol. 2015 Nov;125(2):393-400 PMID: 26376654 PMCID: PMC6094943 SCOPUS ID: 2-s2.0-84945477926 09/18/2015